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1 
Abstract 
Poly(ethylene glycol)-conjugated (or PEGylated) proteins are an increasingly 
important class of therapeutic proteins that offer improved in vivo circulation half 
lives over their corresponding native forms. Their production involves covalent 
attachment of one or more poly(ethylene glycol) molecules to a native protein, 
followed by purification. Because of the extremely high costs involved in producing 
native therapeutic proteins it is important that subsequent PEGylation processes are as 
efficient as possible. In this paper, reaction engineering and purification issues for 
PEGylated proteins are reviewed. Paramount considerations for PEGylation reactions 
are specificity with respect to the conjugation site and overall yield. Batch PEGylation 
reaction methods are discussed, along with innovative methods using packed bed or 
“on-column” approaches to improve specificity and yield. Purification methods are 
currently dominated by ion exchange and size exclusion chromatography. Other 
methods in common use for protein separations, including hydrophobic interaction 
chromatography, affinity chromatography and membrane separations, are rarely used 
in PEGylated protein purification schemes. A better understanding of the effects of 
PEGylation on the physicochemical properties of proteins (isoelectric point, surface 
charge density and distribution, molecular size and relative hydrophobicity) and 
interactions between PEGylated proteins and surfaces is needed for the future 
development of optimal purification processes and media. 
 
 
Keywords:  PEGylation, proteins, biochemical engineering, separations, reaction 
engineering, chromatography 
2 
Introduction 
Poly(ethylene glycol) or PEG is a neutral, hydrophilic polyether which exhibits little 
reactivity unless modified with functional groups.  It has many uses and applications 
including those related to its use as a non-toxic, non-immunogenic lubricant or carrier 
in pharmaceutical formulations.  The polymer can be prepared with relatively 
controlled average MW and modified with various functional groups.  Abuchowski 
and Davis et al. (1977) observed that covalent attachment of PEG to proteins results 
in active conjugates  that are non-immunogenic, non-antigenic and have greatly 
increased in vivo circulation half-lives. These changes appear to be mainly due to 
significantly increased molecular size (hydrodynamic radii), plus surface alteration 
and protection (in effect masking) by the neutral, chemically inert, hydrophilic PEG 
polymers; whose coating effects were also noted by other researchers including Sehon 
et al., Merrill et al., Hoffman et al., Harris et al., Johansson et al., and Holmberg et al. 
(see in Harris, 1992a, b; Harris and Zalipsky, 1997; Veronese and Harris, 2002; 
Zalipsky, 1995). PEGylation of therapeutic proteins reduces renal clearance rates and 
protects from proteolytic and other degradation often resulting in enhanced medical 
efficacy. Other benefits of PEGylation may include improved physical and thermal 
stability, as well as solubility.  The latter is particularly important with regard to 
biopharmaceutical formulation and delivery.  Over the past three decades many 
proteins and other substances have been PEGylated for use as pharmaceuticals, 
reaction catalysts, drug delivery agents, and biopharmaceuticals. Successful protein 
biopharmaceuticals include PEGylated α-interferons, for use in the treatment of 
hepatitis C (PEGasys® from Hoffman-LaRoche and PEG Intron® from Schering-
Plough/Enzon), PEGylated growth hormone receptor antagonist (PEG Somavert® 
from Pfizer), PEG-asparaginase (Oncospar® from Enzon), adenosine deaminase 
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(ADAGEN™® from Enzon), and granulocyte colony stimulating factor (Neulasta® 
from Amgen). Many other PEGylated proteins are currently under development. 
 
Protein PEGylation has been reviewed extensively by many authors including a recent 
review by Veronese and Harris in a special issue of Advanced Drug Delivery Reviews 
dedicated to PEGylation (Veronese and Harris, 2002).  Other notable reviews include 
books edited by Harris (1992b), plus Harris and Zalipsky (1997), as well as papers by 
Zalipsky (1995), Zalipsky and Lee (1992), Roberts et al. (2002), Kodera et al. (1998), 
Greenwald (2001) and Pasut et al. (2004). However apart from a brief 1998 review 
(Bailon and Berthold, 1998), little attention has been paid to production and 
separation aspects related to PEG-proteins.  
 
This review focuses on some biochemical and biomolecular engineering aspects of 
protein PEGylation. Specific issues of clinical efficacy, biomedical effects, biological 
function, analysis and conjugation chemistry are not explored except in so far as they 
are relevant to engineering aspects, which mainly involve reaction engineering 
(physical control of reaction specificity and yield), separations and other aspects 
related to production.  Some of the points discussed are relevant for PEGylation and 
processing of substances other than proteins including lower MW pharmaceuticals, or 
for substances modified by hydrophilic polymers other than PEG. 
 
Processing challenges that arise in the development of PEGylated proteins, as well as 
other PEGylated substances, often concern controlling the position of conjugation 
(positional isomers or PEGamers) and the number of PEG adducts or extent of 
PEGylation (N). Therapeutic drugs should ideally be homogeneous products with 
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well-defined activities, and acceptable side-effects. Variations in the position and 
number of PEG adducts gives rise to variations in characteristics relevant to clinical 
and other application related effects.  These include enzymatic or other activities, 
circulation half-life, immunogenicity and clearance (Harris, 1992b; Harris and 
Zalipsky, 1997; Pasta et al., 1988; Zalipsky, 1995). Product homogeneity can be 
obtained by maximising reaction specificity and/or implementing effective product 
purification.  Given the high cost of producing therapeutic proteins prior to their 
PEGylation, achieving high purity of PEGylated forms at the expense of yield (the 
usual trade-off) is not an economically wise option.  Improving reaction specificity 
and developing effective and efficient purification processes are critical areas where 
the biochemical engineer can make valuable contributions. Several approaches are 
available.  Related engineering can be organised in relation to (a) PEGylation site and 
chemistry engineering, (b) PEGylation reaction engineering, and (c) purification 
process engineering.  The first is affected by recent trends to (i) undertake controlled 
PEGylation at defined protein residues (sites) and (ii) use larger molecular PEG 
molecules in an effort to reduce the number of sites (N) which need to be modified to 
effect the desired results. In addition all three engineering aspects are affected by the 
physical properties of PEG polymers, including their neutral, hydrophilic nature and 
relatively large viscosity radii. 
 
PEGylation Site, Chemistry and Polymer Engineering 
The most common chemistry for PEGylation targets the ε-amino group of surface 
lysine residues. Lysines account for approximately 10% of amino acids in a typical 
protein so most proteins including antibodies have numerous surface-available lysine 
residues, which present both opportunities and challenges. Their availability makes 
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conjugation straightforward but the large number of conjugation sites presents 
difficulty in obtaining a specific number of PEG adducts and gives rise to PEGamer 
mixtures.  Control of PEGylation site(s) reduces random PEGylation.  In one simple 
approach amino group modification can controlled to some extent by reaction pH so 
that conjugation tends to occur at the α-amino of the N-terminal (Kinstler et al., 2002; 
Kinstler et al., 1996).  Lysine or other amine groups are not the only protein (residue) 
groups open to covalent modification.   
 
Specific chemistries can be used to target conjugation to a variety of sites on a protein 
e.g. (Zalipsky, 1995).  Such an approach eliminates problems related to PEGylation 
altering a residue so as to negatively affect the activity of the protein or molecules 
being modified. If the native protein has a free cysteine residue not associated with 
the active site, then conjugation with a thiol-selective functionalised PEG (such as 
maleimide-PEG) may be an option.  However, such cases, when they occur naturally, 
are fortuitous and by no means typical.  Proteins can be engineered by site-directed 
mutation or otherwise chemically modified to fabricate a suitable conjugation site 
(e.g. see Chapman, 2002; Chapman et al., 1999; Roberts et al., 2002; Zalipsky, 1995),  
Such approaches have disadvantages in terms of time to market, cost of development 
and risk compared with developing a PEGylated form of an already-approved protein.  
The latter is significant given that the new mutated or chemically altered protein will 
require more certification to obtain regulatory approval  (see Hoyle, 1991).  
Nevertheless approaches related to PEGylation of mutated or modified proteins may 
be justifiable in terms of ensuring the PEGylated product has adequate activity and 
function (see Chapman, 2002; Harris, 1992b; Harris and Zalipsky, 1997). 
 
6 
Yamamoto et al. (2003) produced a lysine-deficient tumour necrosis factor (TNF), 
which was PEGylated at the N-terminus to avoid PEGylation of lysine residues close 
to the active site in the natural form. Remarkably, despite belief that TNF requires 
some lysine groups for activity, acceptable activity was obtained. Pettit et al. (1996) 
used site directed mutagenesis to control PEGylation and the resulting activity of 
interleukin protein. Yang et al. (2003) used site-directed mutagenesis to insert a free 
cysteine group into human Fv fragments followed by thiol coupling with maleimide-
activated PEG. He et al. (1999) introduced a cysteine group into trichosanthin (the 
native form of which has no cysteines) for PEGylation.  More exotic approaches have 
also been used.  Sato (2002) used enzymatic catalysis with microbial transglutaminase 
for site-specific PEGylation of recombinant interleukin-2. 
 
In many cases modification of a target substance by only one polymer molecule may 
achieve the desired pharmacological or other effects.  One example is PEG-Intron 
which involves monoPEGylation of an interferon by a 12 kDa PEG (Wang et al., 
2002). However in other cases more extensive PEGylation may be required, e. g. total 
addition of 20 to 60 kDa PEG (Fung et al., 1997; Heathcote et al., 1999; Yamaoka et 
al., 1994).  Present availability of 20 to 40 kDa functionalised PEGs makes it possible 
to achieve this with mono- or di-PEGylation.  Such low degrees of PEGylation 
reduces the PEG-protein fractions of varied N, and PEGamers of similar N, which 
must be separated from each other.  Many researchers have related the effects of 
PEGylation to the large viscosity radius of PEGs (e. g. Clark et al., 1996). Recent 
work by the authors suggests that, as measured by  (SEC) chromatography, the 
viscosity radius of a protein that is tetra-PEGylated with 5 kDa PEG is equivalent to 
that which results from mono-PEGylation with a 20 kDa PEG (Fee and Van Alstine, 
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2004). Another reason for reducing N is that negative effects of PEGylation on 
protein activity decrease with N and such factors are more dominant than the MW of 
the PEG coupled to the protein. In the case of antibodies and enzymes binding 
constants tend to directly decrease with N in a semilog manner (e. g. Chapman, 2002; 
Chapman et al., 1999; Clark et al., 1996; Karr et al., 1986; Veronese et al., 1992).  
The main argument for PEGylation involving more sites is that it allows use of 
smaller PEGs which may be more rapidly cleared from the body.  Non-medical uses 
of PEG-proteins may also offer situations where multiple PEGylation sites are 
attractive.  
 
Nevertheless a heterogeneous product mixture results from batch-wise PEGylation 
that includes, depending on the conditions, un-reacted native protein, un-reacted 
functionalised PEG, and PEGylated species with a range of PEGylation sites and 
varying extents of conjugation. Further, functionalised PEG’s such as succinimidyl-
propionic-acid-PEG (PEG-SPA) are readily hydrolysed in water, yielding N-
hydroxysuccinimide and un-reactive PEG residues, adding to the product complexity. 
Hydrolysis of amino-activated PEG’s is generally faster than aminolysis so molar 
excesses of PEG to protein as high as 50:1 may be used (for example, Brumeanu et 
al., 1995). Veronese et al. (1992) described other by-products of PEGylation reaction 
such as cross-linked PEG-proteins, arising from impurities in commercial PEG 
reagents, which, although low level contaminants, may be significant in products 
intended for therapeutic use. Normally monomethoxy PEG reagents (mPEG-x) in 
which one terminal hydroxyl group on the PEG diol is replaced by a methyl group 
area used to prevent bifunctional activity such as cross-linking. 
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Reaction Engineering 
Reaction engineering involves controlling the conditions which influence the reaction. 
This often involves a trade-off between maximising the extent of the reaction and its 
specificity versus minimising cost. In biomolecular engineering, conditions must be 
gentle and the reactor and ancillary equipment must be able to be sterilised. Also, 
regulatory practices require traceability from end products back to source for all 
processes and in general it must be shown that all end products have been through 
identical processes. For these reasons, batch, unidirectional, single-pass processes are 
universally preferred, and these processes must be simple and robust to minimise 
variation between batches. In the case of protein PEGylation, the high cost of raw 
materials (particularly highly purified native protein) implies that maximising reaction 
extent and specificity are critical objectives. 
 
In general only pure protein preparations are PEGylated.  This means that PEGylated 
proteins, which require additional reaction, separation and analysis are inherently 
more expensive to produce. The main reasons for not PEGylating crude protein 
samples (e. g. crude or mildly purified fermentation samples) is to reduce validation 
(Hoyle, 1991) and separation challenges.  These are of particular concern as regards 
production of PEGylated biopharmaceuticals and may be of less concern for other 
types of PEGylated-molecules (e.g. pesticides, catalysts, etc.).  This is especially true 
if the PEGylation reaction can be confined to the target protein in a crude mixture, 
and such PEGylation helps render the desired PEG-protein sample readily separable 
from contaminants. 
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Modern trends are to carry out PEGylations using PEGs functionalised with groups 
which tend to readily hydrolyse.  Such groups, such as NHS or SPA require specific 
care in regard to storage and often require use of excess molar ratio’s of PEGylating 
agent to protein.  This can be costly, especially if such reagents need to be GMP 
grade. Other reaction complications (and cost concerns) are related to rapid exposure 
of the PEG reagent to target protein, and controlled termination of the reaction 
typically via pH modulation.  These requirements introduce the need for effective and 
costly process mixing and monitoring capabilities. Such reagent and process demands 
tend to reflect the high standards of biopharmaceutical production.  If PEG-proteins 
and related substances are to be produced for less demanding applications it may be 
possible to work with nonGMP, slower reacting reagents (e. g. PEG-aldehyde, PEG-
epoxide) which have often been employed in other PEG-related coating applications 
(Harris, 1992b; Harris and Zalipsky, 1997). 
 
Protein PEGylation may be carried out in a batch or fed-batch reactor or in a packed-
bed reactor. A major advantage of the batch or fed-batch reactor is that it is simple to 
operate and easy to clean between batches.  As such this is the main approach of 
choice.  Disadvantages are that the reactants, products and by-products remain in 
contact throughout the reaction process and must be separated after completion of the 
reaction. Batch reaction is particularly suitable when site-specific PEGylation 
chemistry is used.  When a less specific chemistry is used, such as conjugation via ε-
amino groups of lysine residues, both under- and over-PEGylated products are 
inevitable. Mainly mono-PEGylated protein will result from a fed-batch operation if 
the protein is kept in large excess and activated PEG slowly added as the limiting 
reagent but unless there is a partition or other way to constantly remove the 
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PEGylated protein from the reactor, multiple PEGylation will result once appreciable 
amounts of PEGylated protein accumulate in the system. In other words, this method 
can control the extent of PEGylation but only at the cost of very low protein 
conversion. Targeting a specific PEGylation extent greater than N= 1 will invariably 
result in under- and over-PEGylated forms. 
 
Packed-bed or “on-column” PEGylation has been used in attempts to influence both 
the site and the extent of conjugation. Solid-phase synthesis has been used for site-
specific oligopeptide PEGylation (Felix, 1997). In this approach, the molecule is built 
up by tethering a peptide sequence to a solid phase and then adding peptides one at a 
time, with bi-functional PEG being attached at a specific step in the sequence. It may 
have some promise for smaller MW substances but its use for PEGylation of larger 
molecules such as most proteins appears questionable. 
 
On-column PEGylation may be achieved by immobilising the protein to the solid 
phase during PEGylation, achieving at least partial separation by washing the column 
free of reactants and by-products in the mobile phase, and then eluting the product(s). 
Monkarsh et al. (1997) used this technique to PEGylate α-interferon before separating 
the positional isomers. They bound the native protein to an ion exchanger and then 
passed activated PEG through the column. Because PEGylation generally weakens 
(IEX) interactions, they were able to elute the PEGylated protein from the column at 
salt concentrations that did not elute the native form. They then replaced the 
equivalent amount of protein that was eluted and repeated the process. Unfortunately, 
this had virtually no effect on the distribution of PEGylated variants achieved in 
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relation to batch PEGylation as the bound protein still presents multiple binding sites 
to the activated PEG in the mobile phase.  
 
A better approach may be to bind the activated PEG to the solid phase and pass the 
protein through the column. As long as the density of the PEG on the surface is not so 
great that a single protein molecule could bridge between two adjacent PEG 
molecules, mono-PEGylation would occur, with the PEGylated form then remaining 
bound to the column until it can be eluted after washing. Binding the PEG to the solid 
phase requires adding a second functional group to the PEG molecule, which might 
then have to be removed from the final PEG-protein product to avoid potentially 
negative clinical effects. Also, PEGylated surfaces are well-known to exclude proteins 
in solution, so encouraging the protein to come into close enough contact with the 
PEG to allow reaction with the conjugation group might prove difficult. 
 
Others have attempted to use on-column PEGylation to orientate the protein so that 
the active site of the protein is held towards the solid-phase interface, thus hindering 
conjugation at sites that might interfere with activity. This may result in a higher 
activity of the PEGylated form over forms that are PEGylated at random in free 
solution. Lee and Lee (2004) reported that this technique gave site-specific mono-
PEGylation of interferon at the N-terminus using reductive alkylation under acidic 
conditions with a yield of 50 to 60% of loaded native protein. However, the binding 
was on a cation exchange column, which would result in a largely random orientation 
of the protein on the exchanger surface and would thus be unlikely to significantly 
affect reaction specificity.  
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Kinstler et al. (2002) demonstrated site-specific PEGylation of recombinant human 
granulocyte colony stimulation factor (rhGCSF) at the N-terminus using reductive 
alkylation under mildly acidic free-solution conditions (pH 5.0). Wylie et al. (2001) 
showed that pH can significantly affect the PEGylation site, giving a preferential 
PEGylation of histidine with succinimidyl carbonyl-PEG under acidic free-solution 
conditions. Therefore, the on-column method of Lee et al., while achieving the 
advantage of reaction and isolation in a single unit operation, may not affect 
positional isomerism or PEGylation extent. 
 
Baran et al. (2003) used an affinity media (Red Sepharose™ CL-4B, GE Healthcare) 
to protect the active site from access by the PEGylation reagent during on-column 
PEGylation of catalase and asparaginase. They reported higher retention of native 
activity for both proteins compared with literature values related to free solution 
PEGylation.  However some of the latter studies used different chemistry, making it 
difficult to attribute higher retentions of activity to the solid phase technique rather 
than to reaction chemistry. As a result the evidence presented for protection of the 
active site by affinity immobilisation was only indirect. 
  
A different approach to column PEGylation, size exclusion reaction chromatography 
(SERC), was used by Fee (2003), who exploited the differing linear velocities of 
species of differing sizes in SEC to control reaction extent. This method is analogous 
to membrane reactors, which, for example, may be used to control the extent of 
protein hydrolysis by removing products via a semi-permeable membrane once their 
molecular weights fall below a certain level. In SERC, the objective is to remove 
products whose size is larger than the reactants (as in PEGylation). Single pulses of 
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the protein and the activated PEG are injected into the column sequentially, lowest 
molecular size first. The larger reactant has a higher linear velocity so catches up to 
the smaller one such that a moving reaction zone is formed as they migrate through 
the column. As the PEGylated protein formed is larger than either reactant, it moves 
ahead of the reaction zone. With a sufficient length of column, both reaction and 
separation of all species can be achieved in a single unit operation. Control of running 
buffer flow rate, PEG and protein concentrations and injection volumes, pH, 
temperature and media type allow full control over the reaction residence time and 
subsequent separation. Ideally, the activated PEG should be larger than the native 
protein so that a reaction front forms as the PEG catches up with the protein in the 
column. This way, the faster moving PEGylated form will move ahead of the reaction 
front through the (inert) protein band and so escape further PEGylation. In this mode, 
the native protein is converted from the trailing edge of the band toward the leading 
edge, leaving low molecular weight by-products behind. The approach is particularly 
useful with regard to PEGylation as many native proteins of therapeutic interest are 
less than 20 kDa, and smaller in colloidal size than even a 5 kDa PEG molecule. 
 
Purification Engineering 
General Considerations 
Normally, in designing a bioseparation strategy, one seeks to exploit differences in 
physicochemical properties. These properties routinely include molecular size (often 
indirectly inferred from differences in molecular weight) for size exclusion 
chromatography and membrane separations, isoelectric point and surface charge 
distribution for ion exchange chromatography and relative hydrophobicity for 
hydrophobic interaction chromatography. Affinity chromatography, which targets 
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highly specific sites on the protein, is a favored method as it allows for significant 
target purification and concentration. 
 
Purification of PEGylated proteins involves removing all molecular species that are 
not part of the target product. In some cases PEG-protein biopharmaceuticals may be 
comprised of a mixture of PEG-proteins of different grafting ratio (N).  Such a 
mixture may offer optimal performance in terms of activity versus in vivo half life. Of 
course mixtures of PEGamers may be suitable as therapeutics only if they can be 
reproduced in type and relative amounts batch to batch.  
 
If target proteins in a crude protein mixture (e. g. fermentation broth) are PEGylated 
in a specific manner then PEGylation may aid their preliminary purification. For 
example the log of the partition coefficient (K) of PEG-modified proteins between the 
two aqueous phases in a PEG-dextran two polymer, or PEG-salt  two-phase system 
increases directly with degree of PEGylation of the protein (Delgado et al., 1997; 
Harris and Zalipsky, 1997; Karr et al., 1986).  This is fortuitous as cell debris, 
endotoxin, some proteins and other contaminants often partition in favour of the non-
PEG-rich phase. Other approaches may also be possible such as selective precipitation 
of PEG-proteins by calcium or other divalent salts. In such cases subsequent 
purification will be performed in a manner similar to the normal situation where a 
pure protein sample is PEGylated. 
 
PEGylation of a pure protein sample creates two basic types of purification 
challenges.  The first is involves separation of PEG-proteins from other reaction 
products including, but not necessarily limited to, unreacted PEGs and proteins.  The 
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second is sub-fractionation of PEG-proteins on the basis of their degree of PEGylation 
and positional isomerism. One would think that effecting such separations should be 
straight-forward but it can be complicated by several factors related to the nature of 
PEG polymers.   
 
As noted above, such polymers are neutral, hydrophilic and soluble in various 
aqueous solutions, as well as being somewhat hydrophobic and soluble in some 
organic solvents such as acetone, or azeotropes (e.g. methanol/water 3:1 v/v).  The 
amphipathic nature of PEG appears related to the conformations it can have in 
solution (Karlström, 1985) and tend to make PEGs weak surfactants (detergents).  As 
temperature affects these conformational states PEGs tend to be thermally responsive 
and their solubility in aqueous solution decreases inversely with temperature.  PEGs 
are normally soluble in aqueous solution up to 100oC but addition of salts can 
drastically reduce their solubility. Fuctionalisation also affects PEG solubility.  PEGs 
are normally neutral but they can interact via their ether oxygens and terminal groups 
in various weak interactions such as hydrogen bonding or ion chelation.  They are 
often used, together with different salts, to promote selective precipitation or 
crystallisation of proteins.  PEGs represent fairly high MW polymers and they tend to 
increase the viscosities of aqueous solutions. They non-specifically adsorb to surfaces 
and in so doing affect the physical and other properties of such surfaces including 
charge group pKa’s and protein adsorption (Harris, 1992b; Harris and Zalipsky, 
1997).   
 
Given the above it is perhaps not surprising that PEGylation reaction product mixtures 
containing PEGs and PEG-proteins can exhibit foaming, viscosity, and protein or 
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polymer precipitation.  These can lead to a need to reduce feed solution 
concentrations. So too column fouling associated with reduced column life may 
occur, and not be ameliorated by trying to clean the columns with concentrated salt or 
high temperature solutions. It is also understandable that proteins whose surfaces have 
been modified by coating with PEGs should show altered size, charge nature and 
expression, hydropobicity, metal chelation, hydrogen bonding, and affinity 
interactions.  Thus one can expect that chromatographic, filtration and other 
preparative and analytical separation methods related SEC, IEX, hydrophic 
interaction chromatography (HIC), immobilised metal affinity chromatography 
(IMAC), specific affinity and other methods may all be affected.  Analytical methods 
such as gel electrophoresis will also be affected.  
 
Many FDA approved PEG-protein biopharmaceuticals have been developed from 
FDA-approved proteins.  Given FDA approval of PEG, the ideal situation in terms of 
rapid process validation would be to purify PEG-proteins by the same process used 
for the native protein.  This is possible in some cases.  However the above process 
factors related to the nature of PEG, and the separation requirements related to 
fractionation of complex reaction product mixtures often make such approaches 
impractical. 
 
Table 1 lists the proteins, PEGylation reagents and purification methods employed by 
many papers reviewed herein. The table is not intended to be exhaustive but gives a 
representative sample of published methods. (For further examples, the reader is 
referred to references Chapman, 2002; Harris, 1992b; Harris and Zalipsky, 1997; Nho 
et al., 1992). In many cases the methods listed in Table 1 reflect laboratory scale 
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separations. Regardless, the separation methods are dominated by ion exchange and 
size exclusion chromatography. The most common IEX method is cation exhange 
which follows the preference for amine group PEGylation. Ultrafiltration and 
diafiltration are used less commonly and mainly for concentration or buffer exchange 
rather than separation of native and PEGylated forms of proteins. Hydrophobic 
interaction chromatography has not been fully investigated which is of interest given 
that (a) PEGylation should affect protein surface hydrophobicity - increasing or 
decreasing it depending on the native protein’s hydrophobicity, and (b) reverse phase 
chromatography (RPC) has been used in industry to analyse reaction mixtures with 
regard to PEGamers and proteins differing in N (private communication).  Affinity 
chromatography has been used in only one case, for on-column PEGylation. 
 
Given the above, plus the great variation in proteins which are PEGylated and their 
degree of PEGylation, it may not be possible to identify a generic separation process 
for PEG-proteins. However it is possible to list some general considerations.  There 
will be at least three fractions to isolate (PEGs, PEG-proteins and native proteins).  
The PEG-protein fraction will need to be subfractionated on the basis of N with 
perhaps some PEGamer fractionation. Given that PEGs are colloidally active and can 
affect process operating conditions (foaming, viscosity, fouling) they should be 
removed as early as possible. One can take advantage of their properties (size, 
neutrality, hydrophilicity, amphipathic nature) and perhaps use filtration or other (e. g. 
HIC, SEC) approaches. Native proteins will tend to not be very “PEG-like” and may 
be isolated on the basis of their different properties (e.g. often smaller viscosity radii, 
greater surface charge, exposed affinity groups) using methods such as size exclusion, 
ion exchange, HIC, affinity chromatography, or even solubility. PEG-proteins will 
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vary in properties between those which may be modified slightly (e. g. low N and 
small MW PEGs) to those more PEG-like in character.  Surface property variation 
may be related to the weight fraction of PEG in the PEG-protein conjugate (Delgado 
et al., 1997) while size and other properties are related to volume fraction (keeping in 
mind the large viscosity radius contribution of the PEG) (Clark et al., 1996; Fee and 
Van Alstine, 2004). Thus approaches related to fractionation on the basis of size, 
charge, and hydrophobicity may be successful in terms of separating PEG-proteins 
from other reaction product mixture components.  IEX media is generally eluted at 
higher salt concentration while HIC media is loaded under high salt; so normally HIC 
follows IEX. Thus it would thus appear that size exclusion followed by ion exchange 
approaches and then HIC may form the basis for a generic approach.  As noted above 
SEC and IEX appear to be commonly used methods. PEGamer fractionation may 
require more exotic methods such as the above approaches with very long linear 
gradients, or HIC using complex and varied mobile phases.   
 
There is presently no method of choice for PEGamer resolution on the preparative 
scale.  Monkarsh et al. (1997) were able to separate 11 positional isomers of mono-
PEGylated α-interferon using cation exchange chromatography but only in analytical 
scale. Differences between isomers in isoelectric point (pI), surface charge 
distribution and relative hydrophobicity are likely to be subtle and it is doubtful that 
these can be exploited at the preparative scale. Fortunately, to date at least, regulatory 
authorities appear to not have insisted on producing single-PEGylation site, 
molecularly defined PEGylated therapeutic proteins.  
 
Size-Based Separations 
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The species to be separated after PEGylation may be classified according to molecular 
weight, as shown in Table 2.  
 
Desalting with gel filtration will remove low molecular weight species and allow 
buffer exchange into a suitable buffer, such as a volatile buffer prior to freeze drying. 
Maeda et al. (1992) used hollow fibre ultrafiltration to remove < 40,000 MW species 
from the product mix after PEGylation of bilirubin oxidase. Bailon and Berthold 
(1998) included diafiltration in their generic purification scheme for PEGylated 
proteins. Tan et al. (1998) concentrated PEG-methioninase with 30,000 MW cut-off 
membranes. Edwards et al. (2003) used 5 kDa molecular weight cutoff membranes for 
concentrating PEGylated tumour necrosis factor receptor type I (TNF-RI), noting that 
unacceptable product losses occurred when using 10 kDa molecular weight cutoff 
membranes. This is surprising, as TNF-RI has a molecular weight of 55 kDa, and was 
mono-PEGylated with a 30 kDa PEG. The authors advised that they normally 
disregard the contribution of the PEG adduct when choosing a suitable pore size for 
ultrafiltration membranes (Edwards et al., 2003). 
 
Low molecular weight hydrolysis and PEGylation reaction by products and un-
conjugated PEG species are generally only weakly retained by ion exchange, so this 
could be used to remove these species. However, binding of PEGylated proteins 
becomes weaker as PEGylation extent increases. Therefore higher PEGylated species 
may well be contained in the flow through fraction. This is discussed in more detail 
below. 
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Size exclusion chromatography can be used to separate PEGylated species from other 
components but the effectiveness will depend greatly upon the molecular sizes of the 
species involved. While SEC has generally been thought to be unreliable for 
identifying PEGylated proteins from their elution profiles (Christakopoulos et al., 
1998; Fortier and Laliberte, 1993; McGoff et al., 1988; Veronese, 2001) SEC columns 
calibrated in terms of molecular size rather than molecular weight give consistent 
results for protein and PEG standards (Benoit et al., 1966; Fee and Van Alstine, 
2004). Using this technique, Fee and Van Alstine (2004) found that the size of 
PEGylated proteins can be accurately predicted from the radius of an hypothetical 
PEG molecule having the same molecular weight as the total conjugated PEG and the 
native protein radius, using the following equation: 
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; where Rh,PEGprot is the viscosity radius of the PEGylated protein; Rh,prot is the 
viscosity radius of the native protein; and Rh,PEG is the viscosity radius in free solution 
of a single PEG molecule of the same molecular weight as the total conjugated PEG. 
 
For globular proteins, the viscosity radius (in Ångströms) of the molecule (assuming a 
spherical shape) is related to its molecular weight in Da, Mr, prot, by equation 2 (Hagel, 
1998) 
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Kuga (1981) collated data on the viscosity radius of PEG molecules from a range of 
sources and a subset of this data gave the following correlation (r2 = 0.9995) with the 
PEG molecular weight in Da, Mr,PEG (Fee and Van Alstine, 2004): 
 
559.0
,, 1912.0 PEGrPEGh MR =        
  (3) 
 
As a general rule of thumb, preparative-scale size exclusion chromatography 
separates proteins well only if they differ in molecular weight by about 100%. Thus a 
protein of molecular weight x can be separated efficiently from one of 2x. This 
corresponds to a size ratio between molecules, calculated from equation 2, of 1.26. In 
terms of size, a PEG molecule has a much larger hydrodynamic radius than a protein 
of corresponding molecular weight. Therefore, conjugating a single PEG of the same 
or higher molecular weight to protein adds much more to the molecular radius than 
simply doubling the protein molecular weight so these species should be easily 
separable by SEC. For low PEGylation extent then, SEC will be effective but the 
resolution between peaks will be expected to decrease as PEGylation extent increases. 
 
Based on equation 1, figure 1 shows the size ratio between species differing in 
PEGylation extent by a single PEG adduct for a protein of MW 15 kDa. The normal 
guideline for separating proteins with acceptable resolution (i.e. a size ratio of 1.26) is 
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shown as a dotted line. All PEGylated species can be separated from the native 
protein in this case even with just a 2 kDa PEG adduct. Note that as the molecular 
weight of the PEG adduct increases, the ability to separate PEGylated species from 
one another increases. However, as expected, SEC becomes less effective in 
separating between species differing by a single PEG as the extent of PEGylation 
increases. The upper limit for good resolution appears to be between di- and tri-
PEGylated species even for 40 kDa PEG adducts (the largest commercial PEG adduct 
readily available). Only mono- and di-PEGylated species can be efficiently separated 
by SEC when a 5 kDa PEG adduct is used. The curves are closer together for the 
larger molecular weight PEG adducts so larger PEG adducts will not allow separation 
of species with N > 3 from their (N-1) counterparts. Increasing the molecular weight 
of the protein reduces the proportional increase in size with each PEG added. Thus we 
conclude that the upper limit for effective SEC separation of PEGylated proteins 
differing by a single PEG adduct is between di- and tri-PEGylated proteins. This 
separation will become more difficult as the ratio of protein to PEG molecular weight 
increases. 
 
Although the sizes of the target PEGylated species are equal, SEC can purify from its 
under- and over-PEGylated forms a protein that is mono-PEGylated with a 20 kDa 
PEG but not the same protein tetra-PEGylated with a 5 kDa PEG. It is worth repeating 
that the guideline for acceptable resolution between species is for obtaining 
acceptable yield and purity in preparative-scale purifications. For analytical purposes, 
peak elution volumes and therefore species can often be clearly identified at higher 
PEGylation extents. 
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Not shown in Table 2 are positional isomers of the same PEGylation extent, which 
will have identical molecular weights but different biological activities. Positional 
isomers are much more difficult to separate as they have closely similar 
physicochemical properties.  
 
The SEC studies of Fee and Van Alstine suggest that existing SEC media is suitable 
for separation of PEG-proteins from native proteins and moderate fractionation of 
PEG-proteins of differing N. This work also suggests that grafting PEGs to proteins 
results in PEG-protein conjugates where, on the timescales and physical events of 
SEC, the PEG polymers appear to spread over the surface of the protein so as to 
maintain the surface to volume ratio they normally have in solution. This helps 
rationalise how modification of proteins with one PEG polymer can have a 
pronounced effect on both its size (e. g. SEC) and surface (e. g. partition or capture 
chromatography) properties (Delgado et al., 1997; Karr et al., 1986).     
 
Charged-Based Separations 
As noted above common problems with purification of PEG-proteins by IEX and 
other capture methods include a need to work with dilute feed solutions and fouling.  
In addition adsorption capacities in terms of mg protein per ml are often 10X lower 
than is normal for non-PEGylated proteins.  However this may to some extent reflect 
the fact that much of volume of PEG-proteins is related to PEG not protein.  
Capacities of media in terms of mass per ml may be more comparable. IEX 
approaches offer the possibility to effect some separation of PEGs, native proteins, 
and PEGylated proteins in one step.  Given the generally satisfactory performance of 
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SEC media, IEX media is the most commonly used media which may be in need of 
improvement.  
 
Most purification methods in the literature use ion exchange at some stage in the 
process. Invariably it is reported that interaction weakens with increased PEGylation 
extent. To the authors’ knowledge, there has been no systematic study of the effects of 
PEGylation extent, the molecular weight of the PEG adducts or the binding site on ion 
exchange behaviour. 
 
PEG is a neutral polymer but it may affect the charge properties of proteins in three 
ways. First, the presence of the PEG conjugate may shield the surface charges of a 
protein, thereby weakening the binding to ion exchange resins. Second, conjugation to 
amino acid residues that alter their charge nature (e. g. convert amine groups to 
amides) or take on charge at certain pH values alter this potential charge and will 
affect the isoelectric point (pI). Third, protein surface localised PEGs may hydrogen 
bond with acidic or other groups and raise their pKa (Delgado et al., 1997). 
 
Azarkan et al. (1996) used thiol PEGylation as a strategy to purify chymopapain for 
x-ray crystallography and found that PEGylated species bound more weakly to a 
cation exchanger. Since the pI of the protein was unaltered by PEGylation, they 
concluded that charge-shielding was responsible. 
 
Hecht et al. (1996) separated PEGylated from native brain-derived neurotrophic factor 
(BDNF) using a preparative electrofocussing device but were unable to separate 
BDNF of differing PEGylation extent. The authors suggested the reason for this was 
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that the species with differing degrees of PEGylation “probably” varied only in the 
length of PEG chains attached rather than the number, and therefore the pI’s of the 
PEGylated species would not differ. However, the origin of the PEGylated material 
was from authors (Chamow et al., 1994) who described the variation in the degree of 
PEGylation as resulting from differing PEGylation extent using a 5000 MW PEG. 
Nonetheless, it is possible that the pI of the various PEGylated species in Hecht et 
al.’s work did not vary significantly despite differing PEGylation extent. Fee and 
Mason (2004) have shown that changes in pI can be calculated from the amino acid 
sequence of the native protein and the reduction in charged residues by conjugation to 
PEG. Isoelectric focussing was able to resolve proteins with differing PEGylation 
extent when coupled via lysine residues in quantitative agreement with calculated pI 
changes. The change in calculated pI with PEGylation extent depended inversely on 
the slope of the net charge versus pH curve, with acidic and strongly basic proteins 
exhibiting little change in pI with PEGylation. Neutral and slightly basic proteins, on 
the other hand, often exhibit relatively large changes in calculated pI with increasing 
PEGylation extent. Fee and Mason were unable to separate these species by anion or 
cation exchange using running buffers at pH values between their pI values. This 
suggests that pI changes per se are not sufficient to ensure predictable separation on 
the basis of charge. 
 
PEGylation dramatically affects molecular size and this may be reflected in lowered 
ion exchange media capacity due to associated decreases in diffusivity or through 
steric. PEGylated surfaces repel proteins (Harris, 1992b; Harris and Zalipsky, 1997), 
and bound PEG-proteins may hinder adsorption of other PEG-proteins. 
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Brumeanu et al. (1995) found that highly PEGylated species were contained in the 
flow through fraction during anion exchange, while mildly PEGylated species eluted 
at lower salt concentrations than native proteins. They also noted that prior removal of 
free PEG was extremely important in obtaining good resolution. This was also 
reported by McGoff et al. (1988) in charge-reversal capillary zone electrophoresis. 
Sherman et al. (1997) and Olson et al. (1997) showed that increased PEGylation 
decreased the conductivity required for elution. 
 
Figure 2 shows the separation of native and PEG-cytochrome C proteins using a 
prototype sulfopropyl (SP) cation exchange resin from GE Healthcare (Uppsala, 
Sweden).  This media was designed to fractionate PEG-protein reaction mixtures. The 
example shown involved PEGylation with 20 kDa PEG-SPA under conditions which 
resulted in primarily mono- and di-PEGylated protein. The figure clearly shows that 
reaction and hydrolysis by-products are contained in the flow through fraction, as well 
as the bulk of the di-PEGylated form. Mono-PEGylated cytochrome C eluted at a 
lower conductivity than the native protein, with good resolution between the two. 
However, under the conditions studied which featured a fairly steep elution gradient 
the di-PEGylated form was not sharply separated from the mono-PEGylated form.  In 
addition a tail on the flow through peak extended to the mono-PEGylated peak. 
Similar results were observed with SP Sepharose™ Fast Flow media and other 
commercial cation exchange media (data not shown), though with lower capacities, 
broader peaks and poorer resolution.  In a variety of situations the prototype media 
appears to not only offer good selectivity but also much reduced fouling and the 
ability to work with 2x more concentrated feed solutions at linear flows of > 100 
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cm/hr.  Note that faster flow rates may not be desired due to the large viscosity radii 
and slow diffusing nature of the PEGylated proteins. 
Piquet et al. (2002) described large laboratory-scale chromatographic separation of 
PEGylated growth hormone release factor (GRF) using a gram-scale column 20 cm x 
5.5 cm with stepwise elution of monoPEG-GRF. Process yield (including 
PEGylation) was 41% and purity of monoPEG-GRF was approximately 97%.  Hall et 
al. (2004) compared conventional anion and cation exchange media with monolithic 
columns and claimed much faster processing in the latter while analytical separations 
were faster in monolithic columns but with poorer resolution. Chapman et al. (1999) 
fractionated PEGylated antibody fragments using SP Sepharose High Performance 
media. The fragments were modified using PEG-maleimide reagents (25 kDa or 
branched 40 kDa from Nektar Therapeutics, Huntsville, AL, USA) and PEGylated in 
a controlled fashion at low N which favored their purification.  
 
Hydrophobicity Based Separation 
Very little work has been done on utilising hydrophobicity for separation. Clark et al. 
(1996) fractionated growth hormone modified with 5 kDa PEG-NHS (N = 0 to 6) 
using a process which began with HIC fractionation of the reaction product mixture 
on a phenyl TSK 5PW™ HIC column loaded at 2.75 mg of protein per ml media 
followed by elution with salt gradient 0.35M NaCitrate, 0.05M Tris pH 7.5 to 0.05M 
Tris at 60 cm/hr for 7 column volumes.  This was followed by ultrafiltration, buffer 
exchange on a G-25 Sephadex™ column and then cation exchange on SP Sepharose 
High Performance media loaded at 2.1 mg protein per ml media and eluted with 7 
column volumes and a gradient from 0 to 300 mM NaCl in 25 mM NaAcetate of N 
amers on SP Sepharose High Performance media run at pH 4 and loaded at 2.1 mg 
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protein per ml gel with elution in 7 column volume gradient from 0 to 300 mM NaCl 
in 25 mM.  
 
PEG forms a biphasic system at high salt concentrations. Vincintelli et al. (1999) 
examined the salting out effects of potassium fluoride and ammonium sulphate on 
PEG and related these to the effectiveness of hydrophobic interaction 
chromatography. They showed that PEG 4600 and native bovine β-lactoglobulin co-
eluted on Fractogel TSK-Butyl 650 but that the conjugate was more tightly bound to 
the matrix, concluding that conformational changes to the protein may contribute to 
the surface hydrophobicity. Another explanation is that the PEG may surround the 
surface of the protein in such a way as to shield hydrophilic regions while leaving 
hydrophobic regions exposed.  The authors and colleagues have noted interesting 
results with HIC (not shown) and this is an approach that requires more investigation. 
 
Immunoaffinity and Other Specific Affinity Interactions 
PEGylation can affect affinity interactions in two basic ways depending on whether 
the target or the binding protein is PEGylated. A general observation is that binding 
constant logarithms increase directly with N.  This holds for enzymes, antibodies and 
other affinity proteins. However PEGylation may also eliminate binding depending on 
the site of modification. Karr et al. noted that significantly PEGylated polyclonal 
antibody preparations were capable of recognising and binding antigen and could be 
used for immunoaffinity separations (Karr et al., 1986).  They also noted that PEG-
modified protein A was also capable of binding antibody (Karr et al., 1988). Many 
studies (Chapman, 2002) suggest that even low level PEGylation of antibodies can 
significantly affect Fc receptor binding.  Veronese et al. (1992) investigate antibody 
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interactions with PEGylated proteins and noted similar results. Thus kd for antibody 
binding of PEG-ribonuclease decreased from 7.6 x 10-8M to 1.3 x 10-7M to 1.2 x 10-
6M as N went from 0 to 4 to 9.  The above suggest that affinity interactions may be 
used to fractionate PEG-protein reaction mixtures and possibly even to sub-fractionate 
PEG-proteins.  However care should be taken to undertake such separations under 
conditions where expensive affinity columns will not become fouled. 
 
Conclusions 
PEG-proteins as well as other polymer-conjugates present new challenges with regard 
to engineering both their preparation and purification.  In many cases such challenges 
are related to such basic factors as polymer properties, and conjugation chemistry, as 
well as how these combine to alter the modified substance.  Basic research related to 
elucidating these properties and effects should pay large dividends in terms of helping 
engineers design processes to deliver effective new products at reasonable costs. 
Research areas of particular interest also include improving control over PEGylation 
site, and separation of both PEG-reaction product mixtures as well as PEGamers.  
Some applications may benefit from the use of non-classical approaches such as two-
phase partitioning, or on the column methods such as size exclusion reaction 
chromatography.  While classic separation methods such as SEC, IEX and HIC are 
useful there is some concern that present media, which has typically been designed for 
macromolecules of smaller viscosity radius than many PEG-proteins, do not offer 
optimal performance.  Though much work needs to be done it is promising to note 
that in many cases PEGylation may render proteins more similar and amenable to 
related process engineering solutions. 
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 Table 1: PEGylated Protein Processing 
 
Protein PEG MW 
Target 
Product 
N 
Conjugation 
Method 
Purification 
Step 
Purification Step 
Purpose Reference 
alpha interferon 
2b 
PEG Intron® 
(Schering-
Plough) 
12 
kDa 1 
succinimidyl 
carbonate PEG 
ion exchange 
 
size exclusion 
 
cation exchange 
isolation of mono-PEG 
form 
 
analysis of species 
 
separation of positional 
isomers 
(Wang et al., 
2002) 
tumour necrosis 
factor receptor 
type I 
30 
kDa 1 
aldehyde PEG 
sodium 
cyanoborohydride 
cation exchange 
 
 
 
 
ultrafiltration/dialysis 
removal of unreacted 
PEG and sodium 
cyanoborohydride 
then gradient NaCl to 
separate PEGylated 
forms 
 
concentration and 
buffer exchange 
(Edwards et 
al., 2003) 
alpha interferon 
2a 
PEGasys® 
(Hoffmann-La 
Roche Inc.) 
40 
kDa 1 
N-hydroxy 
succinimide PEG
(branched) 
ion exchange isolation of mono-PEG form 
(Reddy et 
al., 2002) 
staphylkinase 
5, 10, 
20 
kDa 
1 
site-directed 
mutagenesis 
insert of cysteine, 
maleimide PEG 
size exclusion 
 
cation exchange 
 
 
size exclusion 
desalting 
 
concentration of 
protein species 
 
separation of 
PEGylated forms 
(Moreadith 
and Collen, 
2003) 
tumour necrosis 
factor alpha 
(lysine deficient 
mutant) 
5 kDa 1 
site-specific N-
terminal, 
succinimidyl 
propionate PEG 
size exclusion isolation of mono-PEG form 
(Yamamoto 
et al., 2003) 
alpha interferon 
2a 
20 
kDa 1 
on-column 
reductive 
alkylation 
cation exchange reaction and isolation of mono-PEG form 
(Lee and 
Lee, 2004) 
rat beta-
interferon 
20 
kDa > 1 
propionaldehyde 
PEG 
cation exchange 
 
 
ultrafiltration 
 
 
size exclusion 
removal of reaction 
byproduucts 
 
concentration of 
protein species 
 
separation of native 
and PEGylated forms 
(Arduini et 
al., 2004) 
gelonin 2, 5 kDa various 
succinimidyl 
succinate 
ultrafiltration 
 
size exclusion 
removal of unreacted 
PEG 
 
fractionation of 
PEGylated forms 
(Arpicco et 
al., 2002) 
chymopapain 5 kDa various dithiopyridyl cation exchange removal of native protein 
(Azarkan et 
al., 1996) 
chympapain 5 kDa 1, 2 dithiopyridyl 
cation exchange 
 
hydrophobic 
interaction 
fractionation of native 
and PEGylated forms 
 
removal of native 
protein 
(Azarkan et 
al., 2003) 
asparaginase, 
catalase 5 kDa 
69 
(reported) 
on-column 
affinity 
PEGylation with 
trichloro triazine 
affinity Procion Red 
 
 
diafiltration 
reaction with 
protection of active site 
 
desalting and buffer 
exchange 
(Baran et al., 
2003) 
immunoglobulins 5 kDa various trichloro-triazine 
ultrafiltration 
 
size exclusion 
 
 
anion exchange 
 
 
concentration 
 
removal of unreacted 
PEG 
 
isolation of mildly 
PEGylated forms 
 
(Brumeanu 
et al., 1995) 
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dialysis/ultrafiltration buffer 
exchange/concentration 
insulin 750 Da 1, 2 
nitrophenyl 
chloroformate size exclusion 
fractionation of native 
and PEGylated forms 
(Calceti et 
al., 2004) 
immunoadhesin 5 kDa 7.7 – 14.4 aldehyde IDA/Cu+ removal of unreacted PEG 
(Chamow et 
al., 1994) 
granulocyte 
hormone 
releasing factor 
5 kDa 1, 2 succinimidyl ester ion exchange 
fractionation of 
PEGylated forms 
(Esposito et 
al., 2003) 
α-lactalbumin, 
β-lactoglobulin, 
BSA 
5 kDa 1, 2, 3 
on-column, 
succinimidyl 
propionate, N-
hydroxy 
succinimide 
size exclusion reaction and separation simultaneously (Fee, 2003) 
α-lactalbumin, 
β-lactoglobulin, 
BSA 
2, 5, 
10, 
20, 40 
kDa 
1 - 8 
succinimidyl 
propionate, N-
hydroxy 
succinimide 
size exclusion analytical separation 
(Fee and 
Van Alstine, 
2004) 
myelopoietin 30 kDa 1 aldehyde 
anion exchange 
 
cation exchange 
isolation of mono-
PEGylated form 
(Hall et al., 
2004) 
trichosanthin 5, 20 kDa 1, 2 maleimide 
cation exchange 
 
size exclusion 
fractionation of 
PEGylated forms 
 
analytical separation 
(He et al., 
1999) 
insulin 
750 
Da, 2 
kDa 
1 succinimidyl propionate 
dialysis 
 
lyophilisation 
recovery of PEGylated 
form 
(Hinds and 
Kim, 2002) 
staphylokinase 5 kDa 1 maleimide 
size exclusion 
 
 
unspecified 
chromatography 
analytical separation 
 
isolation of mono-
PEGylated form from 
native protein and free 
PEG 
(Johnson et 
al., 2003) 
epidermal 
growth factor 
2, 5 
kDa 1 - 3 
succinimidyl 
propionate, 
succinimidyl 
succinamide 
dialysis and 
lyophilisation 
 
 
size exclusion 
buffer exchange to stop 
reaction and recover 
product 
 
analytical separation 
(Kim et al., 
2002) 
human 
granyulocute 
colony-
stimulating 
factor 
6, 12, 
20, 
25, 30 
kDa 
1 aldehyde 
size exclusion 
 
 
cation exchange 
analytical separation 
 
isolation of mono-
PEGylated form 
(Kinstler et 
al., 2002) 
anti-interleukin-8 
F(ab’)2 
20, 40 
kDa 1 - 4 
succinimidyl 
propionate, N-
hydroxy 
succinimide 
size exclusion 
 
 
ion exchange 
analytical separation 
 
removal of unreacted 
PEG and isolation of 
PEGylated forms 
(Koumenis 
et al., 2000) 
immunoglobulin 
antigen binding 
domains 
(Fv fragments) 
2, 3.4, 
5, 10, 
12, 20 
kDa 
various 
hydazide 
hydrochloride, 
trichlorophenyl 
carbonate, N-
hydroxy 
succinamide, 
succinimidyl 
carbonate, 
thiazolidine-2-
thione, 
bifunctional 
succinimidyl 
carbonate 
size exclusion isolation of PEGylated forms 
(Lee et al., 
1999b) 
salmon 
calcitonins 
12 
kDa 1, 2 
succinimidyl 
carbonate size exclusion 
fractionation of native 
and PEGylated forms 
(Lee et al., 
1999a) 
salmon 
calcitonin 5 kDa 1 
succinimidyl 
carbonate 
size exclusion 
 
 
reverse phase 
isolation of mono-
PEGylated forms 
 
fractionation of mono-
PEGylated isomers 
(Lee et al., 
1999b) 
epidermal 
growth factor 
3.4 
kDa 1 
N-hydroxy 
succinamide 
size exclusion 
 
 
reverse phase 
isolation of mono-
PEGylated form 
 
fractionation of mono-
PEGylated isomers 
(Lee and 
Park, 2002) 
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lysozyme 2.3 kDa 1 - 3 
Biotinylated N-
hydroxy 
succinamide 
dialysis 
 
size exclusion 
buffer exchange 
 
analytical separation 
(Lee and 
Park, 2003) 
ribonuclease A, 
lysozyme 5 kDa various 
N-succinimidyl 
succinate 
capillary 
electrophoresis analytical separation 
(Li et al., 
2001) 
hemoglobin 
5, 10, 
20 
kDa 
2 maleidophenyl ion exchange isolation of di-PEGylated forms 
(Manjula et 
al., 2003) 
parathyroid 
hormone 
2, 5 
kDa 1 
succinimidyl 
propionate, 
aldehyde 
size exclusion isolation of mono-PEGylated forms 
(Na and Lee, 
2004) 
β-lactoglobulin 5 kDa  
succinimide 
carbonate, 
dithiolpyridyl 
dialysis 
 
 
chromatofocussing 
 
 
hydrophobic  
interaction 
removal of reaction 
byproducts 
 
separation of 
PEGylated forms 
 
separation of 
PEGylated forms 
(Nijs et al., 
1997) 
growth hormone 
releasing factor 
1-29 analogue 
5 kDa 1, 2 
norleucine 
succinimidyl 
ester 
cation exchange isolation of mono-PEGylated form 
(Piquet et al., 
2002) 
interleukin-2 
3, 10, 
12 
kDa 
1 - 3 
enzyme catalysed 
alkylamine  PEG 
conjugation with 
transglutaminase, 
N-hydroxy 
succinimidyl 
PEG 
cation exchange isolation of PEGylated forms (Sato, 2002) 
uricase 5, 10 kDa 1, 2 
norleucine 
succinimidyl 
ester, lysine 
succinimidyl 
ester 
size exclusion/ion 
exchange 
 
 
 
size exclusion 
removal of reaction 
byproducts and 
unreacted PEG 
 
analytical and 
preparative 
fractionation of 
PEGylated forms 
(Schiavon et 
al., 2000) 
tumour nerosis 
factor-RI 
30 
kDa - - ultrafiltration/dialysis 
analytical separations 
for dialysis modelling 
(Stoner et 
al., 2004) 
methioninase 5 kDa 2 - 8 succinimidyl propionate 
ultrafiltration 
 
size exclusion 
 
anion exchange 
removal of unreacted 
PEG 
 
removal of unreacted 
PEG 
 
removal of native 
protein 
(Tan et al., 
1998) 
lysozyme, insulin 5 kDa various 
norleucine 
succinimidyl 
ester 
size exclusion 
 
 
reversed phase 
 
 
ultrafiltration/dialysis 
isolation of PEGylated 
forms 
 
isolation of PEGylated 
forms 
 
concentration and 
buffer exchange 
(Veronese et 
al., 2001) 
BSA, b-
lactoglobulin, 
lysozyme, 
caricain 
4.6 
kDa various 
succinimide 
carbonate, 
dithiolpyridyl 
hydrophobic 
interaction 
fractionation of 
PEGylated forms 
(Vincentelli 
et al., 1999) 
alpha-interferon 
2 b, interleukin 
10 
12 
kDa 1, 2 
succinimidyl 
carbonate 
ion exchange 
 
 
size exclusion 
isolation of mono-
PEGylated form 
 
analytical separation 
(Wylie et al., 
2001) 
anti-tumour 
necrosis factor-α 
scFv fragment 
5, 20, 
40 
kDa 
 maleimide size exclusion analytical separation (Yang et al., 2003) 
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Table 2: Classification of PEGylation products by molecular weight 
 
Low Molecular Weight High Molecular Weight 
• By-products from 
hydrolysis of 
functionalised PEG 
• By-products of PEGylation 
• Buffer components 
 
• Unreacted functionalised PEG 
• Inactive PEG from hydrolysis of PEG–
reagents 
• Native protein 
• Under-PEGylated protein 
• Over-PEGylated protein 
• Target PEGylated protein 
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Figure Captions 
 
 
Figure 1. Ratio of hydrodynamic radii of PEGylated species differing by a single PEG 
adduct. The dotted line shows the normal guideline for obtaining sufficient resolution 
for separation. 
 
 
Figure 2. Separation of native and PEGylated forms of cytochrome C using a 
prototype cation exchange resin designed for PEG-protein fractionation (GE 
Healthcare). 
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Figure 1 
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